Identification of novel splicing variants from RON proto-oncogene pre-mRNA

Moon,Heegyum; Cho,Sunghee; Yang,Xiaoming; Zhou,Jianhua; Loh,Tiing  Jen; Zheng,Xuexiu; Shen,Haihong

doi:10.3892/or.2012.2043

Identification of novel splicing variants from RON proto-oncogene pre-mRNA

Authors:
- Heegyum Moon
- Sunghee Cho
- Xiaoming Yang
- Jianhua Zhou
- Tiing Jen Loh
- Xuexiu Zheng
- Haihong Shen
View Affiliations

Affiliations: School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 500-712, Republic of Korea, JiangSu Key Laboratory of Neuroregeneration, Nantong University, Nantong, P.R. China
Published online on: September 18, 2012 https://doi.org/10.3892/or.2012.2043
Pages: 2217-2220

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

RON is a proto-oncogene that induces cell dissociation, migration and matrix invasion. RON∆160, a splicing variant of RON, is a natural splicing product in colon cancers that is produced through skipping of exons 5 and 6 in alternative splicing process. RON∆160 promotes cellular transformation in vitro and tumor formation in vivo. We present, here, two novel splicing variants of RON in the partial splicing events that involve exons 5 and 6. The common facts of these two novel splicing variants are that exons 4-7 are included. In addition, intron 4 is spliced whereas intron 5 is included in both variants. The difference of these two isoforms is the inclusion or skipping of intron 6. In one variant intron 6 is included, but intron 6 is skipped in another variant. These two variants should be truncated but these proteins have not yet been detected.

View Figures

View References

1	Ronsin C, Muscatelli F, Mattei MG and Breathnach R: A novel putative receptor protein tyrosine kinase of the met family. Oncogene. 8:1195–1202. 1993.PubMed/NCBI
2	Trusolino L and Comoglio PM: Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature reviews Cancer. 2:289–300. 2002. View Article : Google Scholar : PubMed/NCBI
3	Wang MH, Wang D and Chen YQ: Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis. 24:1291–1300. 2003. View Article : Google Scholar : PubMed/NCBI
4	van der Geer P, Hunter T and Lindberg RA: Receptor protein-tyrosine kinases and their signal transduction pathways. AnnuRev Cell Biol. 10:251–337. 1994.PubMed/NCBI
5	Robertson SC, Tynan J and Donoghue DJ: RTK mutations and human syndromes: when good receptors turn bad. Trends Genet. 16:265–271. 2000. View Article : Google Scholar
6	Birchmeier W, Brinkmann V, Niemann C, et al: Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. Ciba Found Symp. 212:230–240. 1997.PubMed/NCBI
7	Niranjan B, Buluwela L, Yant J, et al: HGF/SF: a potent cytokine for mammary growth, morphogenesis and development. Development. 121:2897–2908. 1995.PubMed/NCBI
8	Vande Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I and Resau J: Met-HGF/SF: tumorigenesis, invasion and metastasis. Ciba Found Symp. 212:119–154. 1997.PubMed/NCBI
9	Comoglio PM, Tamagnone L and Boccaccio C: Plasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growth. Exp Cell Res. 253:88–99. 1999. View Article : Google Scholar : PubMed/NCBI
10	Xu XM, Zhou YQ and Wang MH: Mechanisms of cytoplasmic{beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase. J Biol Chem. 280:25087–25094. 2005.
11	Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ and Wang MH: Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res. 261:229–238. 2000. View Article : Google Scholar : PubMed/NCBI
12	Lu Y, Yao HP and Wang MH: Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett. 257:157–164. 2007. View Article : Google Scholar : PubMed/NCBI
13	Gaudino G, Follenzi A, Naldini L, et al: RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J. 13:3524–3532. 1994.PubMed/NCBI
14	Skeel A, Yoshimura T, Showalter SD, Tanaka S, Appella E and Leonard EJ: Macrophage stimulating protein: purification, partial amino acid sequence, and cellular activity. J Exp Med. 173:1227–1234. 1991. View Article : Google Scholar : PubMed/NCBI
15	Bezerra JA, Witte DP, Aronow BJ and Degen SJ: Hepatocyte-specific expression of the mouse hepatocyte growth factor-like protein. Hepatology. 18:394–399. 1993.PubMed/NCBI
16	Danilkovitch A and Leonard EJ: Kinases involved in MSP/RON signaling. J Leukoc Biol. 65:345–348. 1999.PubMed/NCBI
17	Danilkovitch-Miagkova A and Zbar B: Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 109:863–867. 2002. View Article : Google Scholar : PubMed/NCBI
18	Wang MH, Montero-Julian FA, Dauny I and Leonard EJ: Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein. Oncogene. 13:2167–2175. 1996.PubMed/NCBI
19	Santoro MM, Collesi C, Grisendi S, Gaudino G and Comoglio PM: Constitutive activation of the RON gene promotes invasive growth but not transformation. Mol Cell Biol. 16:7072–7083. 1996.PubMed/NCBI
20	Camp ER, Liu W, Fan F, Yang A, Somcio R and Ellis LM: RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol. 12:273–281. 2005. View Article : Google Scholar : PubMed/NCBI
21	Rodrigues GA and Park M: Oncogenic activation of tyrosine kinases. Curr Opin Genet Dev. 4:15–24. 1994. View Article : Google Scholar : PubMed/NCBI
22	Wang MH, Lee W, Luo YL, Weis MT and Yao HP: Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol. 213:402–411. 2007. View Article : Google Scholar
23	Wang MH, Kurtz AL and Chen Y: Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis. 21:1507–1512. 2000. View Article : Google Scholar : PubMed/NCBI
24	Wang MH, Lao WF, Wang D, Luo YL and Yao HP: Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain. Cancer Biol Ther. 6:1121–1129. 2007. View Article : Google Scholar : PubMed/NCBI
25	Collesi C, Santoro MM, Gaudino G and Comoglio PM: A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol. 16:5518–5526. 1996.
26	Zhou YQ, He C, Chen YQ, Wang D and Wang MH: Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene. 22:186–197. 2003. View Article : Google Scholar
27	Eckerich C, Schulte A, Martens T, Zapf S, Westphal M and Lamszus K: RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant. J Neurochem. 109:969–980. 2009. View Article : Google Scholar : PubMed/NCBI